- Home
- SNCY vs XNCR Comparison
SNCY vs XNCR Comparison
Compare SNCY & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | XNCR |
|---|---|---|
| Founded | 1982 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 881.9M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SNCY | XNCR |
|---|---|---|
| Price | $16.17 | $11.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $19.50 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 666.7K | 648.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,126,769,000.00 | $125,576,000.00 |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $7.51 | $4.80 |
| P/E Ratio | $37.60 | ★ N/A |
| Revenue Growth | 4.74 | ★ 13.65 |
| 52 Week Low | $10.14 | $6.92 |
| 52 Week High | $22.29 | $18.69 |
Technical Indicators
Market Signals| Indicator | SNCY | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 49.68 |
| Support Level | $15.36 | $10.83 |
| Resistance Level | $17.93 | $12.87 |
| Average True Range (ATR) | 0.65 | 0.58 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 49.16 | 49.60 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.